Original ArticleMesotheliomaProgrammed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Keywords
Cited by (0)
Disclosure: Dr. Quispel-Janssen has received grants from Bristol-Myers Squibb. Dr. Zimmermann has received grants from Bristol-Myers Squibb. Dr. Thunnissen has received personal fees from Histogenex. Dr. Monkhorst has received grants from RocheDx; and has received personal fees from Pfizer, Bristol-Myers Squibb, MSD, RocheDx, and Abbvie. Dr. Schouten has received grants from Bristol-Myers Squibb. Dr. Disselhorst has received grants from Bristol-Myers Squibb. Dr. Burgers has received grants from Bristol-Myers Squibb; and has received personal fees from Boehringer, Roche, and Astra Zeneca. Dr. Buikhuisen has received grants from Bristol-Myers Squibb. Dr. Baas has received grants from Bristol-Myers Squibb and MSD; and has received personal fees from Bristol-Myers Squibb, MSD, Astra Zeneca, and Targovax. The remaining authors declare no conflict of interest.